

RECEIVED
OPPT CBIC**Via Electronic Submission**

ExxonMobil Chemical Company
13501 Katy Freeway
Houston, TX 77079-1398
281.870.6113 Telephone
281.588.2522 Facsimile

Susan K. Blevins 2000 SEP 26 AM 7:40
Manager
Global Product Stewardship & Regulatory Affairs

ExxonMobil
Chemical

September 25, 2008

Administrator
US Environmental Protection Agency
P. O. Box 1473
Merrifield, VA 22116
Attention: Chemical Right-to-Know Program


Re: Gases, Petroleum, Extractive, C4-6 Isopentene Rich Reaction Products with Methanol, Ether Fraction, Hydrogenated, Cracked, Isopentene Fraction, CAS No. 108083-44-9 for the HPV Challenge Program (ExxonMobil Chemical Company Registration Number for HPV Challenge Program)

To Whom It May Concern:

ExxonMobil Chemical Company (EMCC) is strongly committed to the chemical industry's Responsible Care® program and takes seriously its commitment to the responsible manufacture, testing, and safe use of its products. Under the U.S. Environmental Protection Agency (EPA) High Production Volume (HPV) Chemical Challenge Program (Program), ExxonMobil Chemical Company committed to voluntarily compile a Screening Information Data Set (SIDS) that can be used for an initial hazard assessment of the Gases, Petroleum, Extractive, C4-6 Isopentene Rich Reaction Products with Methanol, Ether Fraction, Hydrogenated, Cracked, Isopentene Fraction (C4-6 IRRP Fraction), CAS No. 108083-44-9. Although there are no data for the stream, based on its composition, it was determined that data for three constituents can be used to characterize the SIDS endpoints because they comprise a large fraction of the stream and therefore, will define the fate and effects of the stream. The three substances are n-hexane (CAS No. 110-54-3), 2,4-dimethylpentane (CAS No. 108-08-7), and cyclohexane (CAS No. 110-82-7).

With this letter, EMCC submits the test plan and robust study summaries compiled into separate dossiers for the three main constituent substances in the C4-6 IRRP Fraction stream. Sufficient data and information exist to characterize all endpoints in the HPV Program. Therefore, no additional testing is proposed. With the submission of this test plan and dossiers, EMCC has completed its commitment under the HPV Program for the C4-6 IRRP Fraction stream.

Please contact me if you require any further information on the status of EMCC commitments to the U.S. HPV Program.



Sincerely,

Susan K. Blevins
Global Product Stewardship and Regulatory Affairs Manager
Email: susan.k.blevins@exxonmobil.com

Attachment

Bcc:

EMCC - Houston

R. Brown
C. Fairbrother

EMBSI - Clinton

A. Bachman
R. Davi
T. Parkerton
K. Pavkov
D. Winkelmann

